Ardent Health Partners (ARDT) Financials

$13.14 -0.41 (-3.03%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$13.15 +0.01 (+0.08%)

As of 06/13/2025 05:50 PM Eastern

Annual Income Statements for Ardent Health Partners

This table shows Ardent Health Partners' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	31	54	210
Consolidated Net Income / (Loss)	265	129	300
Net Income / (Loss) Continuing Operations	108	129	300
Total Pre-Tax Income	311	152	363
Total Operating Income	154	150	337
Total Gross Profit	1,539	3,025	3,431
Total Revenue	5,130	5,409	5,966
Operating Revenue	5,130	5,409	5,966
Total Cost of Revenue	3,591	2,384	2,535
Operating Cost of Revenue	3,591	2,384	2,535
Total Operating Expenses	1,385	2,875	3,095
Selling, General & Admin Expense	1,201	2,425	2,626
Depreciation Expense	138	141	146
Other Operating Expenses / (Income)	47	309	322
Total Other Income / (Expense), net	0.00	1.61	26
Other Income / (Expense), net	-	1.61	26
Income Tax Expense	46	23	63
Net Income / (Loss) Attributable to Noncontrolling Interest	76	75	89
Basic Earnings per Share	$1.50	$0.43	$1.59
Weighted Average Basic Shares Outstanding	126.12M	126.12M	132.44M
Diluted Earnings per Share	$1.50	$0.43	$1.58
Weighted Average Diluted Shares Outstanding	126.12M	126.12M	132.74M
Weighted Average Basic & Diluted Shares Outstanding	-	-	142.75M

This table shows Ardent Health Partners' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2023	9/30/2023	6/30/2024	9/30/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	33	21	43	26	41
Consolidated Net Income / (Loss)	56	39	67	46	59
Net Income / (Loss) Continuing Operations	56	39	67	46	59
Total Pre-Tax Income	68	46	82	57	74
Total Operating Income	67	46	84	54	53
Total Gross Profit	770	782	847	815	840
Total Revenue	1,369	1,378	1,471	1,450	1,497
Operating Revenue	1,369	1,378	1,471	1,450	1,497
Total Cost of Revenue	598	596	624	635	658
Operating Cost of Revenue	598	596	624	635	658
Total Operating Expenses	703	736	763	760	787
Selling, General & Admin Expense	596	621	647	644	670
Depreciation Expense	35	35	36	37	36
Other Operating Expenses / (Income)	72	80	80	80	80
Total Other Income / (Expense), net	0.52	0.00	-1.64	2.81	21
Other Income / (Expense), net	0.52	0.00	0.26	2.81	21
Income Tax Expense	12	7.26	15	11	15
Net Income / (Loss) Attributable to Noncontrolling Interest	23	18	24	20	18
Basic Earnings per Share	$0.26	$0.17	$0.34	$0.19	$0.30
Weighted Average Basic Shares Outstanding	126.12M	126.12M	126.12M	137.11M	140.06M
Diluted Earnings per Share	$0.26	$0.17	$0.34	$0.19	$0.29
Weighted Average Diluted Shares Outstanding	126.12M	126.12M	126.12M	137.54M	140.70M
Weighted Average Basic & Diluted Shares Outstanding	-	-	142.76M	142.73M	143.04M

This table details how cash moves in and out of Ardent Health Partners' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-262	-19	119
Net Cash From Operating Activities	-38	222	315
Net Cash From Continuing Operating Activities	-38	222	315
Net Income / (Loss) Continuing Operations	265	129	300
Consolidated Net Income / (Loss)	265	129	300
Depreciation Expense	138	141	146
Amortization Expense	5.70	4.99	5.47
Non-Cash Adjustments To Reconcile Net Income	-323	-0.75	26
Changes in Operating Assets and Liabilities, net	-125	-52	-162
Net Cash From Investing Activities	47	-138	-220
Net Cash From Continuing Investing Activities	47	-138	-220
Purchase of Property, Plant & Equipment	-151	-137	-188
Acquisitions	0.00	0.00	-36
Divestitures	206	0.00	4.30
Other Investing Activities, net	-8.69	-0.58	-1.71
Net Cash From Financing Activities	-270	-102	25
Net Cash From Continuing Financing Activities	-270	-102	25
Repayment of Debt	-28	-146	-106
Repurchase of Common Equity	-1.95	-26	-9.53
Payment of Dividends	-244	-64	-73
Issuance of Debt	0.88	132	3.60
Issuance of Common Equity	0.00	0.00	209
Other Financing Activities, net	2.50	1.87	0.35
Cash Interest Paid	91	82	75
Cash Income Taxes Paid	56	19	42

This table details how cash moves in and out of Ardent Health Partners' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2023	12/31/2023	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	40	-7.10	229	-6.36	-62
Net Cash From Operating Activities	89	67	90	120	-25
Net Cash From Continuing Operating Activities	89	67	90	120	-25
Net Income / (Loss) Continuing Operations	39	11	46	141	59
Consolidated Net Income / (Loss)	39	11	46	141	59
Depreciation Expense	35	36	37	38	36
Amortization Expense	1.42	0.72	1.38	1.23	1.24
Non-Cash Adjustments To Reconcile Net Income	0.39	-5.09	8.42	13	8.03
Changes in Operating Assets and Liabilities, net	13	25	-2.86	-73	-129
Net Cash From Investing Activities	-25	-57	-45	-105	-23
Net Cash From Continuing Investing Activities	-25	-57	-45	-105	-23
Purchase of Property, Plant & Equipment	-25	-57	-43	-81	-23
Acquisitions	-	-	-0.24	-27	0.00
Other Investing Activities, net	0.24	0.74	-0.80	-0.97	-0.21
Net Cash From Financing Activities	-24	-18	183	-20	-14
Net Cash From Continuing Financing Activities	-24	-18	183	-20	-14
Repayment of Debt	-4.06	-128	-1.50	3.21	-2.45
Payment of Dividends	-19	-13	-21	-20	-19
Issuance of Debt	-	130	1.80	-	0.00
Other Financing Activities, net	-0.98	-6.99	1.74	-3.07	7.86

This table presents Ardent Health Partners' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2023	2024
Period end date	12/31/2023	12/31/2024
Total Assets	4,732	4,956
Total Current Assets	1,618	1,833
Cash & Equivalents	438	557
Accounts Receivable	775	743
Inventories, net	105	115
Prepaid Expenses	77	114
Other Current Assets	222	304
Plant, Property, & Equipment, net	811	862
Total Noncurrent Assets	2,302	2,261
Goodwill	845	852
Intangible Assets	77	77
Noncurrent Deferred & Refundable Income Taxes	32	12
Other Noncurrent Operating Assets	1,348	1,320
Total Liabilities & Shareholders' Equity	4,732	4,956
Total Liabilities	3,649	3,434
Total Current Liabilities	994	945
Short-Term Debt	19	9.23
Accounts Payable	475	401
Accrued Expenses	501	535
Total Noncurrent Liabilities	2,655	2,488
Long-Term Debt	1,168	1,086
Other Noncurrent Operating Liabilities	1,487	1,403
Commitments & Contingencies	0.00	0.00
Redeemable Noncontrolling Interest	7.30	1.16
Total Equity & Noncontrolling Interests	1,075	1,521
Total Preferred & Common Equity	671	1,131
Preferred Stock	0.00	0.00
Total Common Equity	671	1,131
Common Stock	497	756
Retained Earnings	155	366
Accumulated Other Comprehensive Income / (Loss)	19	9.74
Noncontrolling Interest	404	390

This table presents Ardent Health Partners' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2024	9/30/2024	3/31/2025
Total Assets	4,609	4,800	4,911
Total Current Assets	1,501	1,691	1,761
Cash & Equivalents	335	563	495
Accounts Receivable	721	706	777
Inventories, net	105	108	120
Prepaid Expenses	136	120	130
Other Current Assets	205	194	239
Plant, Property, & Equipment, net	807	815	857
Total Noncurrent Assets	2,300	2,294	2,293
Goodwill	852	852	877
Intangible Assets	77	77	77
Noncurrent Deferred & Refundable Income Taxes	35	35	16
Other Noncurrent Operating Assets	1,336	1,331	1,324
Total Liabilities & Shareholders' Equity	4,609	4,800	4,911
Total Liabilities	3,446	3,413	3,347
Total Current Liabilities	909	887	830
Short-Term Debt	11	12	18
Accounts Payable	371	369	372
Accrued Expenses	527	506	440
Total Noncurrent Liabilities	2,537	2,526	2,517
Long-Term Debt	1,082	1,084	1,091
Other Noncurrent Operating Liabilities	1,456	1,442	1,426
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	3.67	2.39	-0.19
Total Equity & Noncontrolling Interests	1,159	1,384	1,565
Total Preferred & Common Equity	740	1,006	1,175
Preferred Stock	-	0.00	0.00
Total Common Equity	740	1,006	1,175
Common Stock	498	745	764
Retained Earnings	225	252	407
Accumulated Other Comprehensive Income / (Loss)	17	9.49	3.93
Noncontrolling Interest	419	379	390

This table displays calculated financial ratios and metrics derived from Ardent Health Partners' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	5.45%	10.29%
EBITDA Growth	0.00%	-0.03%	73.08%
EBIT Growth	0.00%	-1.34%	139.46%
NOPAT Growth	0.00%	-2.53%	117.88%
Net Income Growth	0.00%	-51.40%	132.37%
EPS Growth	0.00%	-71.33%	267.44%
Operating Cash Flow Growth	0.00%	677.96%	42.10%
Free Cash Flow Firm Growth	0.00%	0.00%	102.88%
Invested Capital Growth	0.00%	0.00%	12.50%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-
Gross Margin	30.00%	55.93%	57.51%
EBITDA Margin	5.80%	5.50%	8.63%
Operating Margin	3.00%	2.77%	5.65%
EBIT Margin	3.00%	2.80%	6.09%
Profit (Net Income) Margin	5.17%	2.38%	5.02%
Tax Burden Percent	85.20%	85.07%	82.55%
Interest Burden Percent	202.69%	100.00%	100.00%
Effective Tax Rate	14.80%	14.93%	17.45%
Return on Invested Capital (ROIC)	0.00%	13.93%	14.29%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	14.30%	17.65%
Return on Net Nonoperating Assets (RNNOA)	0.00%	9.90%	8.73%
Return on Equity (ROE)	0.00%	23.83%	23.01%
Cash Return on Invested Capital (CROIC)	0.00%	-186.07%	2.52%
Operating Return on Assets (OROA)	0.00%	3.20%	7.50%
Return on Assets (ROA)	0.00%	2.73%	6.19%
Return on Common Equity (ROCE)	0.00%	14.77%	15.92%
Return on Equity Simple (ROE_SIMPLE)	0.00%	19.22%	26.49%
Net Operating Profit after Tax (NOPAT)	131	128	278
NOPAT Margin	2.55%	2.36%	4.66%
Net Nonoperating Expense Percent (NNEP)	0.00%	-0.37%	-3.37%
Return On Investment Capital (ROIC_SIMPLE)	-	5.64%	10.63%
Cost of Revenue to Revenue	70.00%	44.07%	42.49%
SG&A Expenses to Revenue	23.41%	44.84%	44.02%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	27.01%	53.16%	51.87%
Earnings before Interest and Taxes (EBIT)	154	152	363
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	298	297	515
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.29	2.15
Price to Tangible Book Value (P/TBV)	0.00	0.00	12.05
Price to Revenue (P/Rev)	0.04	0.04	0.41
Price to Earnings (P/E)	6.17	3.56	11.59
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	16.20%	28.08%	8.63%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.74	1.63
Enterprise Value to Revenue (EV/Rev)	0.00	0.25	0.56
Enterprise Value to EBITDA (EV/EBITDA)	0.00	4.55	6.54
Enterprise Value to EBIT (EV/EBIT)	0.00	8.92	9.27
Enterprise Value to NOPAT (EV/NOPAT)	0.00	10.60	12.11
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	6.10	10.69
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	68.72
Leverage & Solvency	-	-	-
Debt to Equity	0.00	1.10	0.72
Long-Term Debt to Equity	0.00	1.08	0.71
Financial Leverage	0.00	0.69	0.49
Leverage Ratio	0.00	4.37	3.72
Compound Leverage Factor	0.00	4.37	3.72
Debt to Total Capital	0.00%	52.30%	41.84%
Short-Term Debt to Total Capital	0.00%	0.82%	0.35%
Long-Term Debt to Total Capital	0.00%	51.48%	41.48%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	18.13%	14.94%
Common Equity to Total Capital	0.00%	29.57%	43.23%
Debt to EBITDA	0.00	3.99	2.13
Net Debt to EBITDA	0.00	2.52	1.05
Long-Term Debt to EBITDA	0.00	3.93	2.11
Debt to NOPAT	0.00	9.30	3.94
Net Debt to NOPAT	0.00	5.87	1.94
Long-Term Debt to NOPAT	0.00	9.16	3.91
Altman Z-Score	0.00	1.48	2.19
Noncontrolling Interest Sharing Ratio	0.00%	38.01%	30.81%
Liquidity Ratios	-	-	-
Current Ratio	0.00	1.63	1.94
Quick Ratio	0.00	1.22	1.37
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-1,704	49
Operating Cash Flow to CapEx	-25.39%	161.34%	168.01%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	1.14	1.23
Accounts Receivable Turnover	0.00	6.98	7.86
Inventory Turnover	0.00	22.60	22.98
Fixed Asset Turnover	0.00	6.67	7.13
Accounts Payable Turnover	0.00	5.02	5.79
Days Sales Outstanding (DSO)	0.00	52.32	46.45
Days Inventory Outstanding (DIO)	0.00	16.15	15.88
Days Payable Outstanding (DPO)	0.00	72.65	63.06
Cash Conversion Cycle (CCC)	0.00	-4.18	-0.72
Capital & Investment Metrics	-	-	-
Invested Capital	0.00	1,832	2,061
Invested Capital Turnover	0.00	5.91	3.07
Increase / (Decrease) in Invested Capital	0.00	1,832	229
Enterprise Value (EV)	0.00	1,353	3,367
Market Capitalization	192	192	2,438
Book Value per Share	$0.00	$5.32	$7.93
Tangible Book Value per Share	$0.00	($1.99)	$1.42
Total Capital	0.00	2,269	2,617
Total Debt	0.00	1,187	1,095
Total Long-Term Debt	0.00	1,168	1,086
Net Debt	0.00	749	538
Capital Expenditures (CapEx)	151	137	188
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	205	340
Debt-free Net Working Capital (DFNWC)	0.00	643	897
Net Working Capital (NWC)	0.00	624	887
Net Nonoperating Expense (NNE)	-134	-1.37	-22
Net Nonoperating Obligations (NNO)	0.00	749	538
Total Depreciation and Amortization (D&A)	144	146	152
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	3.79%	5.70%
Debt-free Net Working Capital to Revenue	0.00%	11.88%	15.03%
Net Working Capital to Revenue	0.00%	11.53%	14.87%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$1.59
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	132.44M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$1.58
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	132.74M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	142.75M
Normalized Net Operating Profit after Tax (NOPAT)	131	128	278
Normalized NOPAT Margin	2.55%	2.36%	4.66%
Pre Tax Income Margin	6.07%	2.80%	6.09%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	92.02%	49.52%	24.31%
Augmented Payout Ratio	92.75%	69.70%	27.49%

This table displays calculated financial ratios and metrics derived from Ardent Health Partners' official financial filings.

Metric	Q2 2023	Q3 2023	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2023	9/30/2023	6/30/2024	9/30/2024	3/31/2025
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	0.00%	7.47%	5.23%	4.04%
EBITDA Growth	0.00%	0.00%	17.47%	14.88%	19.60%
EBIT Growth	0.00%	0.00%	23.98%	24.14%	31.18%
NOPAT Growth	0.00%	0.00%	23.55%	13.01%	-8.29%
Net Income Growth	0.00%	0.00%	20.20%	18.85%	28.60%
EPS Growth	0.00%	0.00%	30.77%	11.76%	38.10%
Operating Cash Flow Growth	0.00%	0.00%	0.00%	1.19%	-68.75%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.66%	0.00%	-1.43%	0.00%
EBITDA Q/Q Growth	0.00%	-19.13%	0.00%	-20.91%	0.00%
EBIT Q/Q Growth	0.00%	-32.22%	0.00%	-32.13%	0.00%
NOPAT Q/Q Growth	0.00%	-29.98%	0.00%	-35.96%	0.00%
Net Income Q/Q Growth	0.00%	-30.51%	0.00%	-31.30%	0.00%
EPS Q/Q Growth	0.00%	-34.62%	0.00%	-44.12%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-120.73%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-1.26%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-0.06%	0.00%
Profitability Metrics	-	-	-	-	-
Gross Margin	56.29%	56.77%	57.57%	56.19%	56.08%
EBITDA Margin	7.49%	6.02%	8.18%	6.57%	7.46%
Operating Margin	4.92%	3.34%	5.70%	3.74%	3.53%
EBIT Margin	4.95%	3.34%	5.72%	3.94%	4.96%
Profit (Net Income) Margin	4.07%	2.81%	4.55%	3.17%	3.94%
Tax Burden Percent	82.14%	84.20%	81.48%	80.62%	79.47%
Interest Burden Percent	100.00%	100.00%	97.74%	100.00%	100.00%
Effective Tax Rate	17.86%	15.80%	18.52%	19.38%	20.53%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	15.54%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	21.05%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	8.25%
Return on Equity (ROE)	0.00%	0.00%	0.00%	0.00%	23.79%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	6.08%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	4.83%
Return on Common Equity (ROCE)	0.00%	0.00%	0.00%	0.00%	17.87%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	0.00%	26.62%
Net Operating Profit after Tax (NOPAT)	55	39	68	44	42
NOPAT Margin	4.04%	2.81%	4.64%	3.02%	2.81%
Net Nonoperating Expense Percent (NNEP)	0.00%	0.00%	0.35%	-0.85%	-5.52%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	1.57%
Cost of Revenue to Revenue	43.71%	43.23%	42.43%	43.81%	43.92%
SG&A Expenses to Revenue	43.57%	45.05%	43.96%	44.40%	44.78%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	51.37%	53.43%	51.87%	52.44%	52.54%
Earnings before Interest and Taxes (EBIT)	68	46	84	57	74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	102	83	120	95	112
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.26	2.61	1.67
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	34.10	8.86
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.33
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	8.74
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	11.45%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.71	1.84	1.36
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.49
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	5.56
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	7.79
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	10.83
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	9.72
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.94	0.79	0.71
Long-Term Debt to Equity	0.00	0.00	0.93	0.78	0.70
Financial Leverage	0.00	0.00	0.65	0.38	0.39
Leverage Ratio	0.00	0.00	3.96	3.46	3.14
Compound Leverage Factor	0.00	0.00	3.87	3.46	3.14
Debt to Total Capital	0.00%	0.00%	48.45%	44.14%	41.47%
Short-Term Debt to Total Capital	0.00%	0.00%	0.48%	0.49%	0.66%
Long-Term Debt to Total Capital	0.00%	0.00%	47.97%	43.65%	40.80%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	18.74%	15.35%	14.57%
Common Equity to Total Capital	0.00%	0.00%	32.81%	40.51%	43.97%
Debt to EBITDA	0.00	0.00	0.00	0.00	2.08
Net Debt to EBITDA	0.00	0.00	0.00	0.00	1.15
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	2.05
Debt to NOPAT	0.00	0.00	0.00	0.00	4.05
Net Debt to NOPAT	0.00	0.00	0.00	0.00	2.24
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	3.98
Altman Z-Score	0.00	0.00	0.00	0.00	1.97
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	24.89%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	0.00	1.65	1.91	2.12
Quick Ratio	0.00	0.00	1.16	1.43	1.53
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	-1,853	-1,876	-2,136
Operating Cash Flow to CapEx	0.00%	354.48%	0.00%	206.37%	-108.20%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-976.03	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	1.23
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	7.76
Inventory Turnover	0.00	0.00	0.00	0.00	21.36
Fixed Asset Turnover	0.00	0.00	0.00	0.00	7.03
Accounts Payable Turnover	0.00	0.00	0.00	0.00	6.91
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	47.05
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	17.09
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	52.80
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	11.33
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.00	0.00	1,921	1,920	2,178
Invested Capital Turnover	0.00	0.00	0.00	0.00	5.53
Increase / (Decrease) in Invested Capital	0.00	0.00	1,921	1,920	2,178
Enterprise Value (EV)	0.00	0.00	1,373	3,538	2,965
Market Capitalization	192	192	192	2,624	1,963
Book Value per Share	$0.00	$0.00	$5.87	$7.05	$8.23
Tangible Book Value per Share	$0.00	$0.00	($1.50)	$0.54	$1.55
Total Capital	0.00	0.00	2,255	2,483	2,673
Total Debt	0.00	0.00	1,093	1,096	1,108
Total Long-Term Debt	0.00	0.00	1,082	1,084	1,091
Net Debt	0.00	0.00	758	533	613
Capital Expenditures (CapEx)	0.00	25	0.00	43	23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.00	269	252	454
Debt-free Net Working Capital (DFNWC)	0.00	0.00	603	816	949
Net Working Capital (NWC)	0.00	0.00	593	803	931
Net Nonoperating Expense (NNE)	-0.43	0.00	1.34	-2.26	-17
Net Nonoperating Obligations (NNO)	0.00	0.00	758	533	613
Total Depreciation and Amortization (D&A)	35	37	36	38	37
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	7.53%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	15.75%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	15.46%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.34	$0.19	$0.30
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	126.12M	137.11M	140.06M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.34	$0.19	$0.29
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	126.12M	137.54M	140.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	142.76M	142.73M	143.04M
Normalized Net Operating Profit after Tax (NOPAT)	55	39	68	44	42
Normalized NOPAT Margin	4.04%	2.81%	4.64%	3.02%	2.81%
Pre Tax Income Margin	4.95%	3.34%	5.59%	3.94%	4.96%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	44.30	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	35.99	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	24.88%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	24.88%

Frequently Asked Questions About Ardent Health Partners' Financials

When does Ardent Health Partners's financial year end?

According to the most recent income statement we have on file, Ardent Health Partners' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Ardent Health Partners' net income changed over the last 2 years?

Ardent Health Partners' net income appears to be on an upward trend, with a most recent value of $299.71 million in 2024, rising from $265.37 million in 2022. The previous period was $128.98 million in 2023. Find out what analysts predict for Ardent Health Partners in the coming months.

What is Ardent Health Partners's operating income?

Ardent Health Partners's total operating income in 2024 was $336.80 million, based on the following breakdown:

Total Gross Profit: $3.43 billion
Total Operating Expenses: $3.09 billion

How has Ardent Health Partners revenue changed over the last 2 years?

Over the last 2 years, Ardent Health Partners' total revenue changed from $5.13 billion in 2022 to $5.97 billion in 2024, a change of 16.3%.

How much debt does Ardent Health Partners have?

Ardent Health Partners' total liabilities were at $3.43 billion at the end of 2024, a 5.9% decrease from 2023, and a 5.9% decrease since 2023.

How much cash does Ardent Health Partners have?

In the past 1 years, Ardent Health Partners' cash and equivalents has ranged from $437.58 million in 2023 to $556.79 million in 2024, and is currently $556.79 million as of their latest financial filing in 2024.

How has Ardent Health Partners' book value per share changed over the last 2 years?

Over the last 2 years, Ardent Health Partners' book value per share changed from 0.00 in 2022 to 7.93 in 2024, a change of 792.7%.

Related Companies

This page (NYSE:ARDT) was last updated on 6/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardent Health Partners (ARDT) Financials

Frequently Asked Questions About Ardent Health Partners' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardent Health Partners (ARDT) Financials

Annual Income Statements for Ardent Health Partners

Quarterly Income Statements for Ardent Health Partners

Annual Cash Flow Statements for Ardent Health Partners

Quarterly Cash Flow Statements for Ardent Health Partners

Annual Balance Sheets for Ardent Health Partners

Quarterly Balance Sheets for Ardent Health Partners

Annual Metrics And Ratios for Ardent Health Partners

Quarterly Metrics And Ratios for Ardent Health Partners

Frequently Asked Questions About Ardent Health Partners' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools